Agilent DNA Microarray Scanner (G2565BA, Agilent Technologies) using the default settings for miRNA Microarray (miRNA Microarray System Protocol, Agilent Technologies) and image provided by the scanner was analyzed using Feature Extraction software version 10 (Agilent Technologies).
mRNA microarrays: One-Color Microarray-Based Gene Expression Analysis Protocol (Agilent Technologies, Palo Alto, CA, USA) was used to amplify and label RNA. Briefly, 1 µg of total RNA was reverse transcribed using T7 promoter Primer and MMLV-RT. Then cDNA was converted to aRNA using T7 RNA polymerase, which simultaneously amplifies target material and incorporates cyanine 3-labeled CTP. Subsequently, samples were hybridized to Whole Human Genome Microarray 4 x 44K (G4112F, Agilent Technologies). 1.65 mg of Cy3 labeled aRNA were hybridized for 17 hours at 65ºC in a hybridization oven (G2545A, Agilent) set to 10 rpm in a final concentration of 1X GEx Hybridization Buffer HI-RPM, according to manufacturer's instructions (One-Color Microarray-Based Gene Expression Analysis, Agilent Technologies). Arrays were washed according to manufacturer's instructions (One-Color Microarray-Based Gene Expression Analysis, Agilent Technologies) and were dried out using a centrifuge. Finally, Arrays were scanned at 5mm resolution on an Agilent DNA Microarray Scanner (G2565BA, Agilent Technologies) using the default settings for 4x44k format one-color arrays and the images provided by the scanner were analyzed using Feature Extraction software (Agilent Technologies). mRNA array data were normalized using quantiles normalization(2) while miRNA array data were normalized using the VSN method(3) which preserves the biological characteristics of the data while stabilizing the variance across the entire intensity range. Quality control was based on statistical outlier criteria implemented in the Bioconductor package ArrayQualityMetrics; there were no statistical outliers in terms of MA plots, dendrogram or boxplots. After normalization, only those probes present in at least one sample from the microRNA-microarrays and at least 50% of all the samples from the mRNA-microarrays were considered for further analysis. Fifteen different bioinformatics algorithms were developed from GeneCard (www.genecards.org), miRBase (www.mirbase.org), mirwalk (www.umm.uni-heidelberg.de/apps/zmf/mirwalk) and Web gestalt (www.bioinfo.vanderbilt.edu/webgestalt) databases for studying the "in silico" complementarity between miRNAs/mRNA (4-6). (GEO reference: GSE84201. Referees accession link upon request).
Epigenetic validation: CpG island identification, DNA extraction, bisulfite modification, bisulfite sequencing and methylation-specific PCR The occurrence of CpG islands (CGIs) encompassing microRNA genes or being located nearby (2000 bp 5-upstream) was assessed using various CGI-revealing programs; we first used CGI Searcher, (http://bioinfo.itb.cnr.it/cgi-bin/wwwcpg.pl) under Takai and Jones parameters: GC ≥55%; Obs/Exp ≥65; and length ≥200 bp, because these situations exclude most of the Alu-repetitive elements (7, 8) . To confirm the CGI position, we used ENCODE annotation data (http://www.genome.ucsc.edu/index.html). CGIs containing repetitive elements were detected using the RepeatMasker Web Server (http://www.repeatmasker.org) and then excluded from the study.
The possible gene in which the miRNA was encoded was also analyzed, followed by an analysis of the presence of 5´ CGIs located in the transcriptional site and at least 1000 bp upstream. For BS, primers were designed, when possible, to exclude binding to any CpG dinucleotide to ensure amplification of either methylated or unmethylated sequences (Supplementary Table 3 ). PCR reactions were used for cell lines and control studies, and performed under the following conditions: Tables   Supplementary Table 1 The GenePrint® 10 System allows co-amplification and three-color detection of ten human loci: TH01, TPOX, vWA, Amelogenin, CSF1PO, D16S539, D7S820, D13S317, D21S11 and D5S818. These loci collectively provide a genetic profile with a random match probability of 1 in 2.92 × 109 and are used for human cell line and tissue authentication and identification and human cell line cross-contamination determination. 
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Supplementary Figure 1: (A)
Effect of cisplatin on cell viability. Viability curves showing the acquired resistance of H23 and H460 cell lines; Cells were exposed for 72 h to each drug concentration. Data were normalized to the untreated control, which was set at 100% and represent the mean + SD of at least 3 independent experiments performed in quadruplicate at each drug concentration tested for every one cell analyzed. IC50, is the inhibitory concentration that kills 50% of the cell population. Resistant index (RI) calculated as IC50 resistant / IC50 sensitive cell line. p<0.001 was considered as a significant change in drug sensitivity (Student's t-test). (B-C) Relative expression levels of the selected miRNAs measured by qRT-PCR. Data are represented in log10 scale and are expressed using the corresponding sensitive (S) line as a calibrator. Each miRNA level was normalized to RNU48 as an endogenous control. Assays were made in the lung cancer cell lines H23 (B) and H460 (C) in all experimental conditions: S, R and RT. S: sensitive; R: resistant; RT: resistant treated with epigenetic reactivation drugs (5-Aza and TSA). The expression number assays for each miRNA are indicated in Supplementary Table 2 . 
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